FEMY News and Press, Femasys Inc. From 09/25/23

2023-09-25 18:28:27 ET More on Femasys Seeking Alpha’s Quant Rating on Femasys Historical earnings data for Femasys Financial information for Femasys For further details see: Femasys up 205% as FDA clears fertility treatment

- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ® , an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is a...

ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including two lead revolutionary late-clinical stage product candidates and FDA-c...

ATLANTA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovative diagnost...

2023-08-31 10:11:51 ET More on Femasys Femasys stock dips on $3.9M equity offering Femasys rises on Canada approval of directional insemination product FemaSeed Femasys hits 52-week low, closes down 20% on significantly higher volume Femasys joins the Russell...

ATLANTA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovative diagnosti...

2023-08-10 10:04:57 ET Femasys press release ( NASDAQ: FEMY ): Q2 GAAP EPS of -$0.22 misses by $0.02 . Revenue of $0.32M (+6.7% Y/Y) misses by $0.05M . For further details see: Femasys GAAP EPS of -$0.22 misses by $0.02, revenue of $0.32M misses by $0.05M

- Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc ® - Three product approvals achieved in Canada for FemaSeed ® , FemCerv ® and FemCath ® products during the second quarter ...

ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally invasive, in-office technologies for reproducti...

2023-07-28 06:00:00 ET 3 Tips for Investing in Penny Stocks in the AI Industry The allure of the artificial intelligence (AI) industry is undeniable. As AI applications continue to redefine sectors from healthcare to finance, the growth potential is vast. Investors aiming to capitalize ...